Superworth

Macrogenics price to book ratio MGNX

Market value divided by the book value of the company's net assets, since 2014.

Today, Nov 2, 2026
3.5×
10-year median
2.8×
Against its 10-year history
65th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.6× to 14.4×
Peer median
1.5×

Macrogenics' price to book ratio is 3.5× as of Nov 2, 2026.

That is above its ten-year median of 2.8×, higher than on 65% of days in the last ten years.

Over that time it ranged from 0.6× in Apr 2025 to 14.4× in Jun 2026.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.5×1.5×14.4×
20251.5×0.6×2.7×
20241.7×1.7×7.5×
20233.1×1.7×3.7×
20223.4×0.8×3.4×
20213.4×3.4×6.6×
20204.4×1.0×7.9×
20192.1×1.4×4.1×
20181.9×1.8×4.6×
20173.7×2.1×3.8×
20162.4×1.6×3.7×
20153.1×3.0×9.0×
20147.1×3.3×12.2×

Against its peers

Companies in Drug Manufacturers - General nearest Macrogenics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Macrogenics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.